Home Online Celebrity Buzz 1

The Power Of 9.7: 7 Reasons EBioMedicine’s Impact Factor Makes It A Top-Tier Journal

• minute read
Contents

The academic publishing landscape is constantly shifting, but one metric remains a crucial benchmark for journal quality and influence: the Journal Impact Factor (JIF). As of the most recent release from Web of Science, the EBioMedicine journal impact factor has solidified its position as a powerhouse in the medical and biological sciences, confirming its status as a premier venue for high-quality, translational research.

Currently, in December 2025, the journal's standing is stronger than ever, reflecting its commitment to publishing research that bridges the gap between basic science and clinical application. The latest figures and rankings confirm that EBioMedicine is not just a journal of record, but a key driver of innovation across multiple disciplines. This deep dive explores the critical metrics that define its success.

EBioMedicine: Journal Profile and Key Metrics (2023-2025)

EBioMedicine, a premium Gold Open Access journal, is a proud member of The Lancet family of journals, published by Elsevier. Its mission is to be the leading venue for translational biomedical research, covering the entire spectrum from preclinical studies to first-in-human trials.

  • Publisher: Elsevier (part of The Lancet family)
  • Publication Model: Premium Gold Open Access (Fully Open Access)
  • Latest Journal Impact Factor (JIF): 9.700 (Based on Web of Science 2023 release)
  • Alternative JIF/Ranking: 10.8 (JIF)
  • Latest CiteScore: 17.1
  • SCImago Journal Rank (SJR): 3.591 (2024)
  • H-Index: 136
  • Quartile Ranking: Q1 in multiple categories
  • Key Research Categories: Biochemistry, Genetics and Molecular Biology, and Medicine

7 Reasons EBioMedicine’s Impact Factor is a Benchmark for Excellence

The impact factor is more than just a number; it represents the average number of times articles published in the journal over the previous two years were cited in the JCR year. The current EBioMedicine Impact Factor of 9.700 (or 10.8 by some measures) is a testament to the quality and relevance of its published content. Here are the key factors driving its success and topical authority.

1. Exceptional Journal Impact Factor (JIF) and Growth

The JIF of 9.700 (Web of Science 2023) places EBioMedicine firmly in the upper echelon of biomedical journals. This high figure signifies that the research published is highly influential and frequently referenced by other scientists worldwide. A high JIF like this acts as a strong indicator of the journal’s scientific prestige and reliability.

2. Consistent Q1 Quartile Ranking Across Disciplines

A journal's quartile ranking (Q1, Q2, Q3, Q4) indicates its position relative to other journals in the same field. EBioMedicine consistently achieves a Q1 ranking in critical categories, including Medicine, Research & Experimental, Biochemistry, Genetics, and Molecular Biology. Achieving Q1 status in multiple, broad fields demonstrates its wide-ranging topical authority and multidisciplinary relevance, making it a highly desirable target for submissions.

3. High CiteScore Reflecting Long-Term Influence

While the JIF focuses on a two-year window, the CiteScore, which currently stands at 17.1, uses a broader three-year window and includes a wider range of document types. This metric provides a more stable and comprehensive view of the journal's citation performance. A CiteScore in the high teens confirms that EBioMedicine articles maintain their relevance and are cited consistently over a longer period.

4. Focus on Translational Biomedical Research

The journal's core mission is to publish cutting-edge translational biomedical research. This focus is key to its high impact. Translational research, by definition, aims to move findings from basic science to practical clinical applications, directly impacting patient care and public health. This critical bridge between the lab and the clinic inherently generates high-impact, frequently cited papers.

5. Strong Authority in Key Disease Areas

The high citation rates are often driven by key research areas where the journal has established significant authority. These include critical fields such as Immunology, Cancer research, Virology, and Internal medicine. By attracting top-tier manuscripts in these highly competitive and rapidly evolving fields, EBioMedicine ensures its content remains at the forefront of scientific discovery.

6. The Prestige of The Lancet Family

Being part of The Lancet family, one of the most respected and influential groups of medical journals globally, provides an inherent level of prestige and trust. This association ensures rigorous peer review standards, global visibility, and a commitment to ethical publishing, which further enhances the journal's reputation and attracts submissions from leading researchers.

7. Commitment to Gold Open Access

As a premium Gold Open Access journal, EBioMedicine ensures that its published research is immediately and freely available to the global scientific community and the public. This open accessibility maximizes the visibility and potential for citation of every article, contributing directly to its high Journal Impact Factor and overall influence. The removal of paywalls accelerates the dissemination of critical findings, from preclinical studies to novel treatments.

Understanding the Broader Metrics: JIF vs. CiteScore

For authors and institutions, understanding the difference between the Journal Impact Factor (JIF) and the CiteScore is essential when evaluating a journal like EBioMedicine.

The JIF (9.700 / 10.8) is calculated by Clarivate’s Web of Science and is the historical standard for journal evaluation. It is a powerful, though sometimes criticized, metric for assessing immediate, short-term impact.

The CiteScore (17.1) is an Elsevier-owned metric based on Scopus data. It is often seen as a more stable and less volatile measure because it uses a three-year citation window and includes a broader range of document types, providing a more holistic view of the journal’s long-term value in Biochemistry, Molecular Biology, and Medicine. The consistently high values for both metrics confirm EBioMedicine’s sustained excellence.

In conclusion, the latest metrics for EBioMedicine—a JIF near 10, a CiteScore over 17, and a consistent Q1 ranking—establish it as a top-tier publication. For researchers engaged in high-impact translational science, submitting to EBioMedicine offers maximum visibility and credibility, ensuring their work contributes directly to advancing human health.

The Power of 9.7: 7 Reasons EBioMedicine’s Impact Factor Makes It a Top-Tier Journal
ebiomedicine journal impact factor
ebiomedicine journal impact factor

Detail Author:

  • Name : Jaren Morissette
  • Username : armstrong.treva
  • Email : camryn.kovacek@yahoo.com
  • Birthdate : 2007-07-14
  • Address : 975 Ignatius Forks Johnsmouth, MA 00223
  • Phone : +1 (318) 599-6399
  • Company : Stamm, Moore and Maggio
  • Job : Payroll Clerk
  • Bio : Qui quia et architecto non. Rerum odio velit aut et voluptatem facere. Minima iusto at adipisci atque quasi quo sapiente ut.

Socials

instagram:

  • url : https://instagram.com/olson2005
  • username : olson2005
  • bio : Reprehenderit enim sit qui incidunt ut in. Eum nemo minus voluptatem incidunt.
  • followers : 6159
  • following : 2912

facebook:

linkedin:

twitter:

  • url : https://twitter.com/olsonh
  • username : olsonh
  • bio : Itaque est quidem deserunt. Necessitatibus molestiae delectus nemo et. Blanditiis explicabo ratione rerum dolorem. Et ducimus quos autem est ipsa dolorum.
  • followers : 6855
  • following : 786

tiktok:

Random Posts